Companies Solid Biosciences Inc.
Solid Biosciences (SLDB): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Solid Biosciences Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $918,630FY2023
- $4,869,909FY2024
- $5,223,442FY2025
CEO total pay was $5,223,442 in fiscal 2025, up from $4,869,909 in fiscal 2024.
FY2025: salary $650,988 · bonus $449,182 · stock awards $2,318,275 · option awards $1,792,397
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Alexander Cumbo | $650,988 | $449,182 | $2,318,275 | $1,792,397 | $0 | $0 | $12,600 | $5,223,442 |
| President, Chief Executive Officer and Director | ||||||||
| David Tyronne Howton | 513,422 | 265,696 | 1,000,488 | 796,621 | 0 | 0 | 12,600 | 2,588,827 |
| Chief Operating Officer and Secretary | ||||||||
| Gabriel Brooks | 502,164 | 259,870 | 798,634 | 756,790 | 0 | 0 | 10,698 | 2,328,156 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Alexander Cumbo | $5,223,442 | $4,869,909 | $918,630 | ↑ +353,533 |
| David Tyronne Howton | 2,588,827 | 2,563,014 | 648,880 | ↑ +25,813 |
| Gabriel Brooks | 2,328,156 | 2,071,372 | — | ↑ +256,784 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation embodies a pay-for-performance philosophy that supports our business strategy, aligns the interests of our executives with our stockholders and promotes company performance. At the same time, we believe our program does not encourage excessive risk-taking by management.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford (AON Hewitt) |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Gabriel Brooks | OPTION | — | — | — | — | — | $756,790 |
| Alexander Cumbo | OPTION | — | — | — | — | — | 1,792,397 |
| Alexander Cumbo | PRSU | — | — | — | — | — | 2,318,275 |
| Gabriel Brooks | PRSU | — | — | — | — | — | 798,634 |
| David Tyronne Howton | OPTION | — | — | — | — | — | 796,621 |
| David Tyronne Howton | PRSU | — | — | — | — | — | 1,000,488 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Gabriel Brooks | $0 | $0 | $756,790 | 0.0% |
| Alexander Cumbo | 0 | 0 | 1,792,397 | 0.0% |
| David Tyronne Howton | 0 | 0 | 796,621 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Tyronne Howton | RSU | 13,052 | — | $73,613 |
| Gabriel Brooks | RSU | 19,500 | — | 109,980 |
| David Tyronne Howton | Option | 26,097 | 6.77 | — |
| Alexander Cumbo | RSU | 28,613 | — | 161,377 |
| Gabriel Brooks | RSU | 32,813 | — | 185,065 |
| Gabriel Brooks | Option | 35,746 | 2.15 | — |
| David Tyronne Howton | RSU | 44,063 | — | 248,515 |
| Gabriel Brooks | Option | 47,394 | 7.85 | — |
| Alexander Cumbo | Option | 57,222 | 6.77 | — |
| David Tyronne Howton | Option | 63,644 | 7.85 | — |
| Gabriel Brooks | RSU | 71,250 | — | 401,850 |
| David Tyronne Howton | RSU | 75,000 | — | 423,000 |
| Alexander Cumbo | RSU | 90,094 | — | 508,130 |
| Gabriel Brooks | RSU | 112,900 | — | 636,756 |
| Alexander Cumbo | Option | 130,137 | 7.85 | — |
| Gabriel Brooks | Option | 142,500 | 6.17 | — |
| David Tyronne Howton | Option | 150,000 | 6.17 | — |
| Alexander Cumbo | RSU | 168,750 | — | 951,750 |
| David Tyronne Howton | RSU | 169,100 | — | 953,724 |
| Gabriel Brooks | PSU | 176,542 | — | 995,697 |
| David Tyronne Howton | PSU | 238,024 | — | 1,342,455 |
| Alexander Cumbo | Option | 337,500 | 6.17 | — |
| Alexander Cumbo | RSU | 401,600 | — | 2,265,024 |
| Alexander Cumbo | PSU | 508,203 | — | 2,866,265 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Ian SmithIndependent · Board Chair | $75,000 | $75,001 | $372,682 | $0 | $0 | $522,683 |
| Lynne SullivanIndependent · Audit (Chair) · Nominating/Governance | 62,321 | — | 297,685 | 0 | 0 | 360,006 |
| Martin FreedIndependent · Compensation · Clinical (Chair) | 60,553 | — | 297,685 | 0 | 0 | 358,238 |
| Georgia KerestyIndependent · Audit · Compensation (Chair) | 59,990 | — | 297,685 | 0 | 0 | 357,675 |
| Adam StoneIndependent · Audit · Nominating/Governance (Chair) | 57,990 | — | 297,685 | 0 | 0 | 355,675 |
| Sukumar NagendranIndependent · Compensation · Clinical | 53,053 | — | 297,685 | 0 | 0 | 350,738 |
| Clare KahnIndependent · Nominating/Governance · Clinical | 52,053 | — | 297,685 | 0 | 0 | 349,738 |
| Ilan GanotIndependent | 40,000 | — | 297,685 | 0 | 0 | 337,685 |
| Alexander CumboEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $297,685 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 6,000 / 5,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $460,960 |
| Equity awards (grant-date value) | $75,001 |
| All other compensation | $0 |
| Total cost of the board | $535,961 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Solid Biosciences as a peer
Companies that benchmark against SLDB
6 companies name SLDB as a compensation peer
- Adverum Biotechnologies, Inc.ADVMFY2024
- Altimmune, Inc.ALTFY2025
- Definium Therapeutics, Inc.DFTXFY2025
- Editas Medicine, Inc.EDITFY2025
- uniQure N.V.QUREFY2025
- Voyager Therapeutics, Inc.VYGRFY2025
Each company listed discloses SLDB in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SLDB in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Solid Biosciences Inc. | 2025 | Alexander Cumbo | $650,988 | $2,318,275 | $1,792,397 | $0 | $5,223,442 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 72,596,980 | 6,203,634 | 38,755 | 92.13% | Passed |
| 2025 | 2025-06-12 | 57,115,409 | 5,143,882 | 58,001 | 91.74% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 92.13%a |
| 2025 | 2025-06-12 | 91.74%b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Clare Kahn | Director | 2026-06-10 | A | 77,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Martin Freed | Director | 2026-06-10 | A | 77,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lynne Sullivan | Director | 2026-06-10 | A | 77,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Georgia Keresty | Director | 2026-06-10 | A | 77,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ian Smith | Director | 2026-06-10 | A | 77,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| PERCEPTIVE ADVISORS LLC | Director | 2026-06-10 | A | 77,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Stone | Director | 2026-06-10 | A | 77,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sukumar Nagendran | Director | 2026-06-10 | A | 77,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ilan Ganot | Director | 2026-06-10 | A | 77,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ian Smith | Director | 2026-07-02 | A | 3,440 | — | — | Common | Form 4 ↗ |
| Ian Smith | Director | 2026-07-02 | D | 3,440 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ilan Ganot | Director | 2026-10-01 | A | 150,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ian Smith | Director | 2026-10-02 | D | 3,440 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ian Smith | Director | 2026-10-02 | A | 3,440 | — | — | Common | Form 4 ↗ |
| Gabriel Brooks | Chief Medical Officer | 2026-10-18 | D | 9,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gabriel Brooks | Chief Medical Officer | 2026-10-18 | A | 9,750 | — | — | Common | Form 4 ↗ |
| Gabriel Brooks | Chief Medical Officer | 2026-10-19 | D | 4,374 | 6 | 24,582 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (42 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Alexander Cumbo. DEF 14A, filed 2026-04-23. Section “2025 Summary Compensation Table” · page 24. As printed: 5,223,442. View filing ↗
- Section 01, David Tyronne Howton. DEF 14A, filed 2026-04-23. Section “2025 Summary Compensation Table”. As printed: 2,588,827. View filing ↗
- Section 01, Gabriel Brooks. DEF 14A, filed 2026-04-23. Section “2025 Summary Compensation Table”. As printed: 2,328,156. View filing ↗
- Section 03, Gabriel Brooks OPTION. DEF 14A, filed 2026-04-23. Section “E XECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Alexander Cumbo OPTION. DEF 14A, filed 2026-04-23. Section “E XECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Alexander Cumbo PRSU. DEF 14A, filed 2026-04-23. Section “E XECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Gabriel Brooks PRSU. DEF 14A, filed 2026-04-23. Section “E XECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, David Tyronne Howton OPTION. DEF 14A, filed 2026-04-23. Section “E XECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, David Tyronne Howton PRSU. DEF 14A, filed 2026-04-23. Section “E XECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-19. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Ian Smith. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 522,683. View filing ↗
- Section 08, Lynne Sullivan. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 360,006. View filing ↗
- Section 08, Martin Freed. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 358,238. View filing ↗
- Section 08, Georgia Keresty. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 357,675. View filing ↗
- Section 08, Adam Stone. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 355,675. View filing ↗
- Section 08, Sukumar Nagendran. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 350,738. View filing ↗
- Section 08, Clare Kahn. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 349,738. View filing ↗
- Section 08, Ilan Ganot. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 337,685. View filing ↗
- Section 08, Alexander Cumbo. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Clare Kahn 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martin Freed 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynne Sullivan 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Georgia Keresty 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ian Smith 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, PERCEPTIVE ADVISORS LLC 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Stone 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sukumar Nagendran 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ilan Ganot 2026-06-10. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ian Smith 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ian Smith 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ilan Ganot 2026-10-01. Form 4, filed 2026-10-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ian Smith 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ian Smith 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gabriel Brooks 2026-10-18. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gabriel Brooks 2026-10-18. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gabriel Brooks 2026-10-19. Form 4, filed 2026-10-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 92.13% (votes for as printed: 72,596,980). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 91.74% (votes for as printed: 57,115,409). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 460,960 + equity 75,001 + all other 0 = 535,961, summed across the director compensation table rows.
- Solid Biosciences Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Solid Biosciences Inc.'s own proxy. As printed: 5,223,442. View filing ↗